Cell activation and death (apoptosis) induced by IL-2: Ultrastructural evidence

Anticancer Research

Volumn 16, Issue 4 A, 1996, Pages 1775-1780

  Capelli, Enrica ^a   Barni, Sergio ^a   Vaccarone, Rita ^a   Fortis, Claudio ^b   Nano, Rosanna ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Apoptosis; IL 2; Immunotherapy; Ultrastructure

Indexed keywords

RECOMBINANT INTERLEUKIN 2;

APOPTOSIS; ARTICLE; BLOOD CELL; CELL ACTIVITY; CELL CULTURE; CELL STRUCTURE; CELL ULTRASTRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; HISTIOCYTE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; LYMPHOCYTE; PHAGOCYTOSIS; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL;

APOPTOSIS; CARCINOMA, RENAL CELL; CELLS, CULTURED; HUMANS; INTERLEUKIN-2; KIDNEY NEOPLASMS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MICROSCOPY, ELECTRON; RECOMBINANT PROTEINS; REFERENCE VALUES; TIME FACTORS;

EID: 0029783248     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Rosenberg SA, Packard BS, Aebersold PM: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: a preliminary report. New England J Med 25: 319-323, 1988.
2. Atzpodien J, Korfer A, Franks CR, Poliwoda H, Kirchner H: Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet 335: 1509-1512, 1990.
3. Ades E W, Bosse D, Orr S, Gillespie T: Immune responses in humans while receiving adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells: acute anergy to mitogens and recall antigens. Pathobiol 58: 78-83, 1990.
4. Fortis C, Ferrero E, Besana C, Biffi M, Heltai S, Galli L, Borri A, Schoenheit A, Rugarli C: Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients. I. Phenotypic and functional analysis of the peripheral blood mononuclear cells. Cancer Immunol Immunother 32: 161-166, 1990.
5. Rosenthal NS, Hank JA, Kolher PC, Minkoff DZ, Moore KH, Bechhofer R, Hong R, Storer B, Sondel PM: The in vitro function of lymphocytes from 25 cancer patients receiving four to seven consecutive days of recombinant IL-2. J Biol Response Mod 7: 123-139, 1988.
6. Wiebke EA, Rosenberg SA, Lotze MT,: Acute immunologic effects of interleukin-2 therapy in cancer patients: decreased delayed -type hypersensitivity response and decreased proliferative response to soluble antigens. J Clin Oncol 6: 1440-1449, 1988.
7. Capelli E, Nano R, Asti M, Lavezzi L, Rossi A, Cuccia M, Salvucci O. Gerzeli G: Research of the optimal dose of interleukin-2 for the selective growth in vitro of lymphocytes with anti-tumoral cytolitic activity. Europ J Histochem 375: 18, 1993.
8. Nano R, Barni S, Capelli E : Morphological changes of lymphocytes activated with interleukin-2. Haematologica 81: 93-94, 1996.
9. Lenardo MJ: Interleukin-2 programs mouse ab T lymphocytes for apoptosis. Nature 353: 858-861, 1991.
10. Basse F, Herberman RB, Nannmark U, Johansson BR, Hokland M, Wasserman K, Goldfarb RH: Accumulation of adoptively transferred adherent lymphokine-activated killer cells in murine metastases. J Exp Med 174: 479-488, 1991.
11. Griffith KD, Read EJ, Carrasquillo JA, Carter CS, Yang JC, Fisher B, Aebersold P, Packard BS, Yu MY, Rosenberg SA: In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma. J Natl Cancer Inst 81: 1709-1717, 1989.
12. Janssen R, Jongsma J, Noteboom J, Kroesen BJ, Helfrich W, Kal H, The H, De Leij: Interleukin-2 enhances T lymphocyte migration to the tumor site. Proc Am Assoc Cancer Res 34:486, 1993.
13. Bessis M: Réintérpretation des frottis sanguins. Springer- Verlag Berlin Heidelberg 1977.
14. Russel JH, White CL, Loh DY, Meleedy-Rey P: Receptor-stimulated death pathway is opened by antigen in mature T cells. Proc Natl Acad Sci USA 88: 2151-2155, 1991.
15. Wesselborg S, Janssen O, Kabelitz DJ: Induction of activation-driven death (apoptosis) in activated but not resting peripheral blood T cells. J Immunol 150: 4388-4345, 1993.
16. Ucker D, Meyers J, Obermiller PS: Activation-driven cell death II. Quantitative differences alone distinguish stimuli triggering non transformed T cell proliferation or death. J Immunol 149: 1583-1592. 1992.